Overall, we identify in GSK3β a key component of the network regulating N1-ICD stability in CLL, and in AKT and PP2A new druggable targets for disrupting NOTCH1 signaling with therapeutic potential. This evidence concerns the gene AKT1 and B-cell chronic lymphocytic leukemia.